BioMarin treats first patient in Europe with its gene therapy Roctavian

US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) late yesterday announced that an individual in Germany with severe hemophilia A was treated with Roctavian (valoctocogene roxaparvovec-rvox), marking the first time that the gene therapy has been given commercially in Europe.

In August last year, Roctavian became the first gene therapy for hemophilia A, with conditional marketing authorization (CMA) from the European Commission. At that time, BioMarin has revealed that the price of Roctavian per patient will be 1.5 million euros ($1.5 million) net of all discounts and reserves in the European Union, with outcomes-based agreements.

“Today represents an important milestone for the hemophilia community, and for patients and physicians around the world seeking access to Roctavian,” said Jeff Ajer, executive vice president and chief commercial officer at BioMarin, adding: “We look forward to more people gaining access to Roctavian in the rest of Europe, as well as the United States, where Roctavian recently received FDA approval.”